Aimmune therapeutics, inc. (AIMT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-86,432

-66,898

-64,455

-62,878

-54,266

-56,998

-51,702

-52,552

-49,500

-41,166

-31,792

-32,497

-25,870

-25,076

-22,086

-18,139

-15,523

-16,008

-8,991

-7,376

-3,441

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense

1,298

-

-

-

666

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

479

383

382

356

297

316

243

144

141

136

132

125

55

30

19

11

Stock-based compensation expense

10,303

8,343

8,081

8,740

7,765

8,069

8,382

8,674

7,607

4,848

4,079

4,199

3,593

3,548

3,488

3,074

2,531

3,406

1,762

963

26

Non-cash interest expense

2,223

1,177

1,190

1,194

1,065

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium on investment securities

6

132

405

552

542

357

304

200

25

-34

-77

-160

-240

-171

-222

-235

-291

-

-

-

-

Research and development expenses recognized from issuance of common stock

5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables, net

772

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

4,012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-2,429

-34

-1,258

-1,163

-1,433

2,407

-603

155

36

600

812

58

-35

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-611

-

509

360

203

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32

-

200

1

84

Accounts payable

191

1,879

-1,145

3,521

1,945

-5,445

5,574

2,990

-431

-559

1,991

634

249

-601

252

-567

-78

536

705

-668

499

Accrued liabilities

-2,159

1,749

3,177

668

-3,555

5,345

-4,299

3,918

2,448

4,630

1,513

6,895

-1,481

-328

5,817

1,037

277

1,269

-947

2,338

-801

Other liabilities

125

107

292

893

-340

-234

102

390

-183

623

302

176

-14

-12

35

102

215

-

-

-

-

Net cash used in operating activities

-71,800

-52,600

-50,800

-46,171

-45,829

-51,550

-41,261

-36,553

-39,764

-31,927

-24,326

-20,248

-23,104

-22,612

-10,682

-11,737

-11,583

-18,592

-8,304

-4,801

-3,993

Purchase of property and equipment

319

953

2,234

3,488

1,372

1,120

2,057

3,860

2,383

1,173

2,401

1,951

900

940

2,181

3,428

1,116

617

495

552

44

Purchase of investments

32,457

26,923

32,418

21,416

85,564

69,008

59,077

68,934

64,274

20,143

34,532

19,440

55,419

93,641

22,247

18,226

63,064

-

-

-

-

Maturities of investments

37,640

72,367

86,754

59,738

67,408

49,805

36,280

37,816

50,802

49,341

49,180

46,991

33,009

17,250

37,006

42,605

64,086

-

-

-

-

Net cash provided by (used in) investing activities

4,864

44,491

52,102

34,834

-19,528

-20,323

-24,854

-34,978

-15,855

28,025

12,247

25,600

-23,310

-77,331

12,578

20,951

-94

-17,288

-107,285

-612

-44

Cash flows from financing activities:
Borrowings under debt agreement

85,000

0

0

0

40,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs

-

0

0

0

3,856

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of preferred and common stock

199,907

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from underwritten public offering, net of offering costs

-

-

-

-

-

98,000

0

972

189,463

-

-

-

-

-

-

-

-

-

-

-

-

Net cash proceeds from exercise of stock options

1,996

11,108

3,028

3,020

3,250

2,964

2,378

3,392

1,993

-

1,449

385

1,118

2,042

585

171

45

-106

195

16

198

Tax withholdings related to net share settlements of restricted stock units

1,427

0

0

182

490

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

285,476

11,108

3,028

2,838

38,904

100,964

2,378

4,364

191,456

3,568

1,449

385

1,118

147,042

585

171

45

-104

169,748

-1,398

67,081

Effects of changes in foreign exchange rates

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

218,538

3,036

4,280

-8,494

-26,453

29,091

-63,737

-67,167

135,837

-334

-10,630

5,737

-45,296

47,099

2,481

9,385

-11,632

-35,984

54,159

-6,811

63,044

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued liabilities

120

-117

-751

865

1,051

641

104

-1,232

1,788

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for underwritten public offering

-

-

-

-

-

-

-

-

990

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for stock option exercises

-

-

-

-

383

-

-

-

752

-

-

-

-

-

-

-

-

-

-

-

-